HemaSphere (Aug 2023)
P376: VENO-OCCLUSIVE DISEASE RISK AND OTHER OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Marcos de Lima,
- Partow Kebriaei,
- Francesco Lanza,
- Christina Cho,
- Gizelle Popradi,
- Manmeet Kaur,
- Mei-Jie Zhang,
- Fan Zhang,
- Saara Tikka,
- Erik Vandendries,
- Kofi Asomaning,
- Stephanie Dorman,
- Matthias Stelljes,
- David Marks,
- Wael Saber
Affiliations
- Marcos de Lima
- 1 Ohio State University, Blood and Marrow and Cellular Therapy Program, Columbus, United States
- Partow Kebriaei
- 2 MD Anderson Cancer Center, Houston, United States
- Francesco Lanza
- 3 Ospedale di Ravenna, Ravenna, Italy
- Christina Cho
- 4 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, United States
- Gizelle Popradi
- 5 McGill University Health Centre, Montreal, Canada
- Manmeet Kaur
- 6 Center for International Blood and Marrow Transplant Research, MIlwaukee, United States
- Mei-Jie Zhang
- 6 Center for International Blood and Marrow Transplant Research, MIlwaukee, United States
- Fan Zhang
- 7 Pfizer Inc, Shanghai, China
- Saara Tikka
- 8 Pfizer Oy, Helsinki, Finland
- Erik Vandendries
- 9 Pfizer Inc, Cambridge, United States
- Kofi Asomaning
- 9 Pfizer Inc, Cambridge, United States
- Stephanie Dorman
- 10 Pfizer Inc, Ontario, Canada
- Matthias Stelljes
- 11 Universitätsklinikum Münster, Münster, Germany
- David Marks
- 12 University Hospitals Bristol NHS Trust, Bristol, United Kingdom
- Wael Saber
- 6 Center for International Blood and Marrow Transplant Research, MIlwaukee, United States
- DOI
- https://doi.org/10.1097/01.HS9.0000968416.51811.f0
- Journal volume & issue
-
Vol. 7
p. e51811f0
Abstract
No abstracts available.